Jingchen Zhang
Molecular Biology · 2022
A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 7 citations into it
- Biomaterials — 5 citations into it
Whom Jingchen Zhang trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from Jingchen Zhang's perspective
Ordered by how strongly the researchers Jingchen Zhang trusts endorse each paper. Same corpus, a different order for every researcher.
- RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. (Molecular Pharmaceutics)
- Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. (Materials Science and Engineering C: Materials for Biological Applications)
- New Developments in Liposomal Drug Delivery. (Chemical Reviews)
- Doxil®--the first FDA-approved nano-drug: lessons learned. (Journal of Controlled Release)
- Liposome composition in drug delivery design, synthesis, characterization, and clinical application. (Advanced Drug Delivery Reviews)
- A review on phospholipids and their main applications in drug delivery systems
- Design of liposomes as drug delivery system for therapeutic applications. (International journal of pharmaceutics)
- Liposome application: problems and prospects
- Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors (Proceedings of the National Academy of Sciences of the United States of America)
- Transport of molecules across tumor vasculature (Cancer Metastasis Review)